Side-by-side · Research reference

DSIPvsHCG

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/36 cited

BFDA-ApprovedHUMAN-REVIEWED12/52 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

01Mechanism of Action

Parameter

DSIP

HCG

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

LH receptors on testicular Leydig cellsSchröder-Lange 2025

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Feedback intact?

—

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Antibody development

—

Rare with recombinant; possible with urinary-derived formulations

02Dosage Protocols

Parameter

DSIP

HCG

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

—

Lower / starter dose

50 mcg pre-sleep

—

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water

—

Timing

30–60 min pre-sleep

—

Half-life

Short plasma; CNS effects last hours

—

Hypogonadotropic hypogonadism (monotherapy)

—

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

Combined therapy (hCG + FSH)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

Triple therapy (experimental)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

Cryptorchidism (pediatric)

—

500–4,000 IU IM 2–3×/week for 3–6 weeks

Duration to sperm appearance

—

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

Route

—

Intramuscular or subcutaneousKonsam 2026

Monitoring

—

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

04Side Effects & Safety

Parameter

DSIP

HCG

Injection site reaction

Mild irritation

Pain, erythema (mild, transient)

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

—

Gynecomastia

—

Aromatization of elevated testosterone to estradiol; dose-dependent

Testicular discomfort / Edema

—

Rapid testicular growth in hypogonadal males; usually self-limiting

Polycythemia

—

Elevated hematocrit from supraphysiological testosterone; monitor CBC

Mood / Libido changes

—

Variable; usually positive with normalization of testosterone

Acne / Oily skin

—

Androgen-mediated; dose-dependent

Prostate concerns

—

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

Antibody formation

—

Rare with recombinant; possible with urinary-derived

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

05Administration Protocol

Parameter

DSIP

HCG

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

2. Injection site

SQ — abdomen. Rotate sites.

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

3. Timing

30–60 min pre-sleep.

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

5. Needle

29–31G insulin syringe.

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).